Supernus Pharmaceuticals
SUPN
295 hedge funds and large institutions have $1.87B invested in Supernus Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 124 increasing their positions, 84 reducing their positions, and 34 closing their positions.
5,108% more call options, than puts
Call options by funds: $677K | Put options by funds: $13K
48% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 84
12% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 34
0.12% more ownership
Funds ownership: 106.12% → 106.23% (+0.12%)
0% more funds holding
Funds holding: 295 → 295 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $1.94B → $1.87B (-$65.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$24.8M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$22.3M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$8.93M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.05M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$12.3M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$11.5M |
| 3 |
BlackRock
New York
|
-$10.1M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$8.96M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$7.02M |
SUPN Hedge Fund Activity: Q2 2025 in Review
295 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2025, worth a combined $1.87B — down 3.4% from $1.94B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new SUPN positions and 34 closed out — a net gain of 4 holders — while 124 added to existing stakes and 84 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $24.8M. The largest seller was Armistice Capital, cutting an estimated $12.3M.
- 295 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $1.87B of Supernus Pharmaceuticals stock for Q2 2025, down 3.4% quarter-over-quarter.
- 38 funds opened new Supernus Pharmaceuticals positions in Q2 2025 and 34 closed out, a net change of +4 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2025 was Woodline Partners, an estimated $24.8M added.
- The largest Supernus Pharmaceuticals seller in Q2 2025 was Armistice Capital, an estimated $12.3M sold.
Based on aggregated 13F filings for Q2 2025.